We are live on ! Find out more
VBIO

Valion Bio
VBIO

11 hedge funds and large institutions have $206K invested in Valion Bio in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

38% more funds holding

Funds holding: 8 → 11 (+3)

7.58% more ownership

Funds ownership: 14.96% → 22.54% (+7.6%)

12% less capital invested

Capital invested by funds: $233K → $206K (-$27.8K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
+$100K
2
Citadel Advisors
Citadel Advisors
Florida
+$64.5K
3
VF
Virtu Financial
New York
+$34.1K
4
TSS
Two Sigma Securities
New York
+$8.83K
5
UBS Group
UBS Group
Switzerland
+$7.59K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$59.6K
2
HF
HRT Financial
New York
-$27K
3
XT
XTX Topco
Cayman Islands
-$9.31K
4
MG
Marex Group
-$4.35K

VBIO Hedge Fund Activity: Q2 2026 in Review

11 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2026, worth a combined $206K — down 12% from $233K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new VBIO positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Murchinson, opening a new position worth an estimated $100K. The largest seller was Geode Capital Management, cutting an estimated $59.6K.

  • 11 institutional investors held Valion Bio (VBIO) as of Q2 2026, up from 8 in Q1 2026.
  • Funds reported $206K of Valion Bio stock for Q2 2026, down 12% quarter-over-quarter.
  • 4 funds opened new Valion Bio positions in Q2 2026 and 1 closed out, a net change of +3 holders.
  • The largest Valion Bio buyer in Q2 2026 was Murchinson, an estimated $100K added.
  • The largest Valion Bio seller in Q2 2026 was Geode Capital Management, an estimated $59.6K sold.

Based on aggregated 13F filings for Q2 2026.